SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences Limited has filed the final Monitoring Agency Report from CRISIL Ratings covering its October–November 2022 Rights Issue of Rs 39,980.18 lakh (gross) / Rs 39,700.18 lakh (net). The proceeds were earmarked for three purposes: Rs 25,001.48 lakh for pharmaceutical R&D and clinical trials, Rs 5,000 lakh for repaying an inter-corporate deposit from the promoter group, and Rs 9,698.70 lakh for general corporate purposes (GCP). As of March 31, 2025, 100% of the net proceeds have been fully utilized with no deviation from the stated objects. Of the GCP amount, Rs 1,955.11 lakh was reallocated to R&D as permitted by the Letter of Offer, and Rs 254.34 lakh was used for ordinary business expenses. This is the concluding MA report for the issue.
Positive compliance signal — the company has used the entire Rights Issue amount exactly as disclosed, with no deviations or unfavourable events. Full deployment of R&D funds supports the company's drug pipeline (15 NCEs, 5 in clinical stage). Final closure of monitoring removes an overhang and reinforces governance transparency for shareholders.